Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenuto archiviato il 2024-05-30

Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction

Obiettivo

Currently, clinical diagnosis and monitoring of bladder cancer (BC) relies on invasive, highly costly cystoscopy. Additionally, due to high recurrence rates BC treatment is associated with frequent follow-up of patients, making BC one of the most costly types of cancer in terms of management cost. Thus there is a clear clinical need for the development of new approaches for early detection of recurrence and progression.
Our proposal is based on the identification of novel biomarkers (BM) for BC recurrence and progression in urine and powerful technological platforms as extensive foreground work of the involved partners in the framework of FP7 EU projects DECanBio and GENINCA. The objective of TransBioBC is to translate this foreground work in the field of BC and to specifically employ the involved technologies (CE-MS and micro-ELISA), represented by the participating SMEs, for the development of non-invasive urine tests for routine monitoring of BC recurrence and progression. Our project uniquely integrates leading BC clinical experts with experts on proteome analysis and high throughput immunoassay development in an implementation-oriented workflow. Strict monitoring of assay analytical performance, and properly collected and well characterized clinical samples from existing sufficiently powered BC cohorts are combined with in-depth knowledge of regulatory requirements, analysis approaches to define added value and well designed business plans including multi-stakeholder dissemination and exploitation plans.
Collectively, TransBioBC will provide strong evidence for utility of the new BM directly in BC clinical management and as a secondary aim for usage in clinical trials and drug development.

Invito a presentare proposte

FP7-HEALTH-2013-INNOVATION-2
Vedi altri progetti per questo bando

Coordinatore

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Contributo UE
€ 760 964,80
Indirizzo
SORANOU EFESIOU 4
115 27 Athina
Grecia

Mostra sulla mappa

Regione
Αττική Aττική Κεντρικός Τομέας Αθηνών
Tipo di attività
Research Organisations
Contatto amministrativo
Dimitris Raptis (Mr.)
Collegamenti
Costo totale
Nessun dato

Partecipanti (3)